[{"NetIncomeLoss_2_Q2_USD":881099.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":21375000.0,"RepaymentsOfRelatedPartyDebt_2_Q2_USD":null,"AssetsCurrent_0_Q2_USD":814949.0,"AccountsPayableAndAccruedLiabilitiesCurrent_0_Q2_USD":48325.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":573703.0,"IncomeTaxesPaid_2_Q2_USD":156153.0,"OperatingCostsAndExpenses_2_Q2_USD":449872.0,"OperatingCostsAndExpenses_1_Q2_USD":208233.0,"CommitmentsAndContingencies_0_Q2_USD":null,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":8674046.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":8694075.0,"PreferredStockSharesOutstanding_0_Q2_shares":null,"ProceedsFromRelatedPartyDebt_2_Q2_USD":null,"Liabilities_0_Q2_USD":10965109.0,"ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_2_Q2_USD":5000000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":716700.0,"NetIncomeLossAvailableToCommonStockholdersBasic_1_Q2_USD":-157479.0,"TemporaryEquityAccretionToRedemptionValueAdjustment_2_Q2_USD":1167576.0,"TemporaryEquityAccretionToRedemptionValueAdjustment_1_Q2_USD":13891.0,"PaymentsOfStockIssuanceCosts_2_Q2_USD":null,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":null,"AssetsHeldInTrustNoncurrent_0_Q2_USD":291586277.0,"CashAndCashEquivalentsPeriodIncreaseDecrease_2_Q2_USD":-200307.0,"BusinessAcquisitionPercentageOfVotingInterestsAcquired_0_Q2_pure":0.5,"ProceedsFromDecommissioningFund_2_Q2_USD":573703.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_Q2_USD":-161886.0,"PaymentsToInvestInDecommissioningFund_2_Q2_USD":null,"IncomeTaxExpenseBenefit_2_Q2_USD":234469.0,"IncomeTaxExpenseBenefit_1_Q2_USD":-38170.0,"PrepaidExpenseCurrent_0_Q2_USD":98249.0,"NetIncomeLossAvailableToCommonStockholdersBasic_2_Q2_USD":-286477.0,"IncreaseDecreaseInPrepaidExpense_2_Q2_USD":6099.0,"Assets_0_Q2_USD":292409964.0,"RedeemableNoncontrollingInterestEquityCarryingAmount_0_Q2_USD":276444848.0,"NetIncomeLoss_1_Q2_USD":-143588.0,"PreferredStockSharesIssued_0_Q2_shares":null,"AdditionalPaidInCapital_0_Q2_USD":1606168.0,"NonoperatingIncomeExpense_2_Q2_USD":1565440.0,"NonoperatingIncomeExpense_1_Q2_USD":26475.0,"LiabilitiesCurrent_0_Q2_USD":152609.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-774010.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":1115568.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":-181758.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":3392972.0,"TaxesPayableCurrent_0_Q2_USD":104284.0,"StockholdersEquity_0_Q2_USD":5000007.0,"UnrealizedGainLossOnSecurities_2_Q2_USD":-41610.0,"UnrealizedGainLossOnSecurities_1_Q2_USD":-471500.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"DeferredOfferingCosts_0_Q2_USD":16473117.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-0.03,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.02,"CashFDICInsuredAmount_0_Q2_USD":250000.0,"ProceedsFromIssuanceOfWarrants_2_Q2_USD":null,"PreferredStockSharesAuthorized_0_Q2_shares":1000000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":292409964.0,"DeferredIncomeTaxExpenseBenefit_2_Q2_USD":-7085.0,"PreferredStockValue_0_Q2_USD":null,"InvestmentIncomeInterest_2_Q2_USD":1607050.0,"InvestmentIncomeInterest_1_Q2_USD":497975.0,"IncreaseDecreaseInAccruedIncomeTaxesPayable_2_Q2_USD":85401.0,"OperatingIncomeLoss_2_Q2_USD":-449872.0,"OperatingIncomeLoss_1_Q2_USD":-208233.0,"ProceedsFromSaleOfTrustAssetsToPayExpenses_2_Q2_USD":573703.0,"ProfitLoss_1_Q2_USD":-143588.0,"InterestExpenseTrustPreferredSecurities_2_Q2_USD":1224703.0,"Ticker":"CELU","CIK":"1752828","name":"GX ACQUISITION CORP.","OfficialName":"Celularity Inc. Class A Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"2","uom":"USD","footnote":"nan","Market Cap":"1622347796.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200813"}]